Clinical Trial Update: Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety and biological effects of C326, an IL-6 inhibitor, in Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• C326

Snippet

Sponsor: Avidia | Conditions: Crohn's Disease | Phase 1 | Status: UNKNOWN